UM-UC-3 Cells

The UM-UC-3 cell line is derived from a human bladder carcinoma, specifically a high-grade transitional cell carcinoma (TCC), established from a male patient. It has been widely used in cancer research due to its robust growth characteristics, both in vitro and in vivo. UM-UC-3 cells display an epithelial morphology and are aneuploid, with a modal chromosome number ranging from 59 to 95. These cells are capable of forming tumors in immunocompromised mice, with histological features resembling the primary tumor, highlighting their utility as a preclinical model for bladder cancer.

Genetic and molecular studies have revealed significant alterations in UM-UC-3 cells, including frequent deletions and mutations in key tumor suppressor genes such as CDKN2A and CDKN2B. These genes are located in the 9p21 region, which is commonly deleted in bladder cancer, contributing to dysregulation of the cell cycle. Additionally, UM-UC-3 exhibits changes in the phosphatidylinositol 3-kinase (PI3K) signaling pathway, a critical driver of tumorigenesis in urothelial carcinoma. These features make it a valuable model for studying oncogenic signaling pathways and testing targeted therapies.

UM-UC-3 cells have been employed extensively in therapeutic research, particularly in exploring the effects of inhibitors targeting the PI3K/AKT and MAPK signaling pathways. They are also used in drug screening programs to identify compounds effective against bladder cancer. The cell line’s genetic and phenotypic stability over multiple passages further supports its role as a reliable research tool in cancer biology and therapeutic development.